| OAA0302 | Differential susceptibility of cells infected with defective and intact proviruses to HIV-selective cell killing by small molecule therapies | Oral abstract session with live Q&A | Understanding and targeting persistent HIV reservoirs |
| OAA0303 | Follicular T helper cells (TFH) are a minor source of the active HIV reservoir in secondary lymphoid tissues of people with HIV (PWH) on prolonged suppressive antiretroviral therapy (ART) | Oral abstract session with live Q&A | Understanding and targeting persistent HIV reservoirs |
| OAA0304 | Hypoxic adaptation uncovers a glycolytic dependence of HIV-1 latency reversal | Oral abstract session with live Q&A | Understanding and targeting persistent HIV reservoirs |
| OAA0305 | Analysis of HIV transcribing cells from viremic and virally-suppressed individuals living with HIV using novel single-cell RNAseq method | Oral abstract session with live Q&A | HIV virology |
| OAA0402 | Novel V1 deleted-envelope vaccine based on VLP protects against SHIV infection | Oral abstract session with live Q&A | Host immune responses, vaccines and immunotherapies |
| OAA0403 | Perturbation of mucosal granulocytic effector cells in lentivirus infections | Oral abstract session with live Q&A | Host immune responses, vaccines and immunotherapies |
| OAA0404 | Diverse envelope trimers with altered glycan coverage around the CD4-binding site elicit neutralizing antibodies of >50% breadth in NHPs | Oral abstract session with live Q&A | Host immune responses, vaccines and immunotherapies |
| OAA0405 | Protective efficacy of intranasal vaccination with a Sendai virus vector expressing a spike antigen against SARS-CoV-2 infection in mice | Oral abstract session with live Q&A | SARS-CoV-2 virology, pathogenesis, and host immune responses, vaccines and immunotherapies |
| OAB0102 | Persistent accelerated epigenetic aging is associated with altered neuroimaging and immune biomarkers in a longitudinal cohort of vertically-acquired HIV-positive adolescents | Oral abstract session with live Q&A | Antiretroviral therapies and clinical issues in infants, children and adolescents |
| OAB0103 | Is the recommended valganciclovir dosing for treatment of cytomegalovirus in infants adequate for treatment of cytomegalovirus pneumonia in HIV-positive infants in sub-Saharan Africa? A pharmacokinetic sub-study in the EMPIRICAL trial | Oral abstract session with live Q&A | Antiretroviral therapies and clinical issues in infants, children and adolescents |